PC-3M Xenograft Model Service for Prostate Cancer

The PC-3M cell line provides a highly metastatic and clinically relevant in vivo platform for investigating the invasive mechanisms and therapeutic vulnerabilities of advanced prostate cancer. As a premier pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision PC-3M Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your prostate cancer drug discovery and development pipeline.

Overview of PC-3M Xenograft Model for Prostate Cancer

The PC-3M xenograft model is an advanced in vivo translational system widely utilized in oncology research for the study of metastatic prostate carcinoma. Derived as a highly metastatic subline of the parental PC-3 cell line, PC-3M cells exhibit a significantly enhanced capacity for migration, invasion, and metastatic colonization when transplanted into immunodeficient rodent hosts.

Biologically, the PC-3M model is valued for its aggressive phenotypic profile and its ability to recapitulate the systemic spread of human prostate cancer. Like the parental line, PC-3M cells are androgen-independent and lack functional androgen receptor (AR) expression, making them an ideal system for evaluating the efficacy of therapies targeting androgen-independent pathways, anti-angiogenic factors, and metastatic signaling cascades. This model provides a robust system for assessing tumor progression and the systemic dissemination of malignancy in a physiologically relevant in vivo environment, serving as a critical tool for pre-clinical screening programs focused on high-grade prostate malignancies.

Cell Line Information: PC-3M

The PC-3M cell line is a metastatic variant derived from the PC-3 cell line, selected for its superior ability to form metastases in experimental models. These cells maintain stable, aggressive growth characteristics in vitro, offering a high-fidelity system for pre-clinical prostate cancer research.

Our Services

Workflow of PC-3M Xenograft Model Construction

• Cell Culture & Quality Control: Human PC-3M cells are expanded in vitro using certified nutrient media under optimized physiological conditions. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic integrity and purity.
• Host Selection & Preparation: Immunodeficient rodent models are utilized for tumor engraftment, with all animals maintained in a controlled, pathogen-free environment to ensure physiological stability and consistency throughout the study.
• Precision Inoculation: A calibrated suspension of high-viability PC-3M cells is prepared, often supplemented with an extracellular matrix (e.g., Matrigel) to optimize take efficiency. Cells are inoculated in vivo via subcutaneous or orthotopic injection to facilitate the development of a measurable, solid tumor or metastatic lesion.
• Longitudinal Monitoring: Tumor dimensions are measured systematically using digital calipers or imaging modalities to monitor volume progression and potential systemic spread. Animal health, activity, and body weight are recorded periodically to document systemic tolerance and clinical status.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, animals are randomized into experimental cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 1. PC-3M Xenograft Model Construction Workflow

Case Study - PC-3M Xenograft Model Development

A pre-clinical validation study was conducted using the PC-3M xenograft model to evaluate the therapeutic efficacy of a novel anti-metastatic candidate. Following the successful subcutaneous inoculation of PC-3M cells into immunodeficient mice, the host animals developed firm, rapidly growing solid tumors. The treatment group demonstrated a clear, statistically significant inhibition of tumor growth and metastatic progression compared to the vehicle-treated control group, confirming the model's high sensitivity and predictive reliability for screening novel interventions against advanced, metastatic prostate cancer.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing specialized prostate cancer lineages, providing highly reproducible in vivo translational platforms for complex hormonal-resistance research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your prostate cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our PC-3M platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.